This group of infectious disease specialists contributes to the design and implementation of the company’s clinical development strategy in phage therapy.
NANTES, France–(BUSINESS WIRE)–Regulatory News:
Pherecydes Pharma (FR0011651694 – ALPHE) (Paris:ALPHE), biotechnology company specialized in precision phage therapies to treat resistant and/or complicated bacterial infections, announces today the formation of a Medical Advisory Board, composed of leading international scientific and clinical experts specialized in infectious diseases.
“We are happy and honored to be able to cooperate with this group of internationally renowned scientists,” stated Didier Hoch, CEO of Pherecydes Pharma. “Our unique approach to phage therapy was considered particularly promising by these experts, all of whom are very enthusiastic about joining our fight against antibiotic resistance. With their support, we will be able to implement our ambitious development plan in effective way.”
The Board will support Pherecydes Pharma in consolidating its clinical development strategy in phage therapy. It will meet twice a year with a first meeting on September 28, 2022.
The members of the Medical Advisory Board are:
Dr Saima AslamAssociate Professor of Infectious Medicine at UC San Diego, California, USA.
Dr. Aslam is Director of the Solid Organ Transplant Infectious Disease Service and a founding member and clinical director of the Center for Innovative Phage Applications and Therapeutics (IPATH) at the University of California (UC) San Diego. He received his medical degree from Aga Khan University, Pakistan in 1999 and then trained in Internal Medicine and Infectious Diseases at Baylor College of Medicine, Texas, USA. Dr. Aslam also holds a Master of Science in Clinical Research from Baylor College of Medicine. He currently holds several leadership positions with the American Society of Transplantation and the International Society of Heart and Lung Transplantation. Dr. Aslam is the principal investigator of several NIH and industry-funded clinical trials and a leader in clinical applications of phage therapy in the United States. It is also receiving funding from the Cystic Fibrosis Foundation to develop a registry and associated “phage library” for people with cystic fibrosis and infected with the Burkholderia bacteria.
Professor Marc Bonten, Chair of the strategic research program “Infection and Immunity” at the UMC in Utrecht, the Netherlands.
Prof. Marc Bonten obtained his doctorate at the Faculty of Medicine of the University of Maastricht, in the Netherlands. From 2008 to March 2021 he headed the Department of Medical Microbiology at the University Medical Center Utrecht (UMC Utrecht). Since 2003, he is the head of the Infectious Disease Epidemiology Research Group at the Julius Center for Health Sciences and Primary Care and Professor of Molecular Epidemiology of Infectious Diseases. He has been the principal investigator of numerous large-scale epidemiological studies and randomized trials on the prevention and treatment of infectious diseases. He is currently chairman of the strategic research program Infection and Immunity at UMC Utrecht.
Professor Tristan Ferry, Deputy Head of Service in the Infectious and Tropical Diseases Service of HCL Lyon and President of the National Scientific Committee of CRIOACs, France.
Tristan Ferry is a graduate of the University Claude Bernard Lyon 1 and trained in internal medicine and infectious and tropical diseases at the Hospices Civils de Lyon. He is responsible for the regional branch of the Reference Center for Complex Osteo-Articular Infections (CRIOAc Lyon) and of the Lyon Bone and Joint Infection group (a multidisciplinary group with colleagues specialized in the field of infectious diseases, surgery, microbiology, imaging). nuclear medicine and drug pharmacokinetics). His main research topic is the promotion of innovative treatments, systemically and/or locally, in patients with bone and joint infections. He is particularly involved in the promotion and evaluation of phage therapy and the combination of local antibiotics in patients with bone and joint infections. He is one of the members of the inaugural committee of the new ESCMID study group for non-traditional antibacterial therapies (ESGNAT) and was elected, in April 2022, member of the executive committee as clinical leader. Being involved in the national scientific committee of CRIOAc and in the European Society of Bone and Joint Infections (EBJIS), he wants to facilitate the realization of multicenter clinical trials in France and Europe, to evaluate new academic and industrial therapeutic options.
Professor Yok-Ai Que, associate professor of Intensive care medicine at the Bern Hospital, Switzerland.
Pr Yok-Ai Que is Associate Professor of Intensive Care Medicine and Head of Department at Inselspital Bern in Switzerland. He has a PhD and a Masters in Advanced Studies. Professor Yok-Ai Que obtained his doctorate at the CHUV of the University of Lausanne in 1999 and continued his career there until he became a reference physician for intensive care services in 2007 and the chief physician in 2013. During his career, he implemented innovative translational research. and is considered a pioneer in phage therapy. In particular, he submitted 2 patent applications and supervised 5 theses in this field. He is on the reading committees of the main scientific journals and has developed solutions based on artificial intelligence to study the behavior of bacteriophages.
Professor Martin Witzenrath, Director of the Department of Respiratory Diseases and Intensive Care at Charité-Universitätsmedizin Berlin, Germany.
Professor Martin Witzenrath is the medical director of the Charité-Centre for Internal Medicine and Dermatology at Charité-Universitätsmedizin Berlin, where he also holds the chair of Pulmonology and Head of the Department of Respiratory Diseases and Intensive Care. His clinical specialties are pulmonary infections, intensive care medicine, transplantation, interventional bronchiology and pulmonary hypertension. His scientific work includes preclinical, translational and clinical studies in pneumonia, acute respiratory failure and pulmonary hypertension. He is a Fellow of the European Respiratory Society (FERS).
Next financial release:
- Semester results 2022: Thursday, October 27, 2022, after the market
About Pherecydes Pharma
Founded in 2006, Pherecydes Pharma is a biotechnology company that develops treatments against resistant bacterial infections, responsible for many serious infections. The company has developed an innovative approach, precision phage therapy, based on the use of phages, natural viruses that kill bacteria. Pherecydes Pharma develops a portfolio of phages targeting 3 of the most resistant and dangerous bacteria that alone represent more than two thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. The concept of precision phage therapy has been successfully applied to dozens of patients in the context of compassionate treatment, under the supervision of the National Agency for the Safety of Medicines (ANSM). Pherecydes Pharma, whose headquarters are in Nantes, relies on a team of twenty experts from the pharmaceutical industry, biotechnologies and academic research.
For more information, www.pherecydes-pharma.com
This release contains non-factual materials, including, but not limited to, certain statements regarding future results and other future events. These statements are based on the current view and assumptions of the Company’s management. They incorporate known and unknown risks and uncertainties that could cause actual results, profitability and expected events to differ materially. Furthermore, Pherecydes Pharma, its shareholders and their respective affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties about, any statistical information or forward-looking information contained herein. derived from third party sources or industry publications. These statistical data and forward information are used in this press release for informational purposes only.
Thibaut du Fayet
Chief Operating Officer
Dusan Oresansky / Nicolas Fossiez
T: 01 44 71 94 92
T.: 01 44 71 94 98